834 related articles for article (PubMed ID: 10387023)
1. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
2. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
[TBL] [Abstract][Full Text] [Related]
3. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9.
Jean P; Lopez-Garcia P; Dansette P; Mansuy D; Goldstein JL
Eur J Biochem; 1996 Nov; 241(3):797-804. PubMed ID: 8944768
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.
Ha-Duong NT; Dijols S; Marques-Soares C; Minoletti C; Dansette PM; Mansuy D
J Med Chem; 2001 Oct; 44(22):3622-31. PubMed ID: 11606127
[TBL] [Abstract][Full Text] [Related]
5. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
[TBL] [Abstract][Full Text] [Related]
6. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Yamazaki H; Shimada T
Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
[TBL] [Abstract][Full Text] [Related]
7. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.
Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690
[TBL] [Abstract][Full Text] [Related]
8. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
10. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
Poli-Scaife S; Attias R; Dansette PM; Mansuy D
Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
[TBL] [Abstract][Full Text] [Related]
11. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
12. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
13. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Rifkind AB; Lee C; Chang TK; Waxman DJ
Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
[TBL] [Abstract][Full Text] [Related]
14. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
15. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
16. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
17. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.
Ono S; Hatanaka T; Miyazawa S; Tsutsui M; Aoyama T; Gonzalez FJ; Satoh T
Xenobiotica; 1996 Nov; 26(11):1155-66. PubMed ID: 8948091
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.
Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F
Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism.
Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
Biopharm Drug Dispos; 2002 Jul; 23(5):183-90. PubMed ID: 12116049
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
